Morfeas Koumas

Morfeas Koumas

Auto-generated profile, based on publicly available information

Morfeas Koumas

Translational Neuropharmacology Laboratory, Department of Psychology, University of Cyprus, Nicosia, 2109, Cyprus

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in British Journal of Pharmacology
Verified
Journal Article
Open access
AMAndria Michael
Andria Michael
AOAnna Onisiforou
Anna Onisiforou
PGPolymnia Georgiou
Polymnia Georgiou
MKMorfeas Koumas
Morfeas Koumas
CPChris Powels
Chris Powels
PZPanos Zanos
Panos Zanos
Background and Purpose: Opioid use disorder (OUD) is a pressing public health concern marked by frequent relapse during periods of abstinence, perpetuated by negative affective states. Classical antidepressants or the currently prescribed opioid pharmacotherapies have limited efficacy to reverse the negative affect or prevent relapse.Experimental Approach: Using mouse models, we investigated the effects of ketamine's metabolite (2R,6R)‐hydroxynorketamine (HNK) on reversing conditioning to sub‐effective doses of morphine in stress‐susceptible mice, preventing conditioned‐place aversion and alleviating acute somatic abstinence symptoms in opioid‐dependent mice. Additionally, we evaluated its effects on anhedonia, anxiety‐like behaviours and cognitive impairment during protracted opioid abstinence, while mechanistic studies examined cortical EEG oscillations and synaptic plasticity markers.Key Results: (2R,6R)‐HNK reversed conditioning to sub‐effective doses of morphine in stress‐susceptible mice and prevented conditioned‐place aversion and acute somatic abstinence symptoms in opioid‐dependent mice. In addition, (2R,6R)‐HNK reversed anhedonia, anxiety‐like behaviours and cognitive impairment emerging during protracted opioid abstinence plausibly via a restoration of impaired cortical high‐frequency EEG oscillations, through a GluN2A‐NMDA receptor‐dependent mechanism. Notably, (2R,6R)‐HNK facilitated the extinction of opioid conditioning, prevented stress‐induced reinstatement of opioid‐seeking behaviours and reduced the propensity for enhanced morphine self‐consumption in mice previously exposed to opioids.Conclusions and Implications: These findings emphasize the therapeutic potential of (2R,6R)‐HNK, which is currently in Phase II clinical trials, in addressing stress‐related opioid responses. Reducing the time and cost required for development of new medications for the treatment of OUDs via drug repurposing is critical due to the opioid crisis we currently face.

8 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
AOAnna Onisiforou
Anna Onisiforou
MKMorfeas Koumas
Morfeas Koumas
AMAndria Michael
Andria Michael
PZPanos Zanos
Panos Zanos
Background: Opioid abstinence induces persistent emotional disturbances and widespread neuroplastic changes, in areas of the brain including the hippocampus. Although ketamine and its metabolite ( 2R,6R )-hydroxynorketamine (HNK) show potential in reversing opioid abstinence-related deficits in rodents, the molecular mechanisms underlying their efficacy remain poorly understood. Methods: Male C57BL/6J mice underwent a 3-week opioid abstinence paradigm, followed by a single (2R,6R)-HNK (10 mg/kg, i.p.) or saline injection on day 28. Sucrose and social preference tests were used to assess behavioral deficits. We conducted RNA sequencing of ventral hippocampal tissue from these mice, followed by differential gene expression and functional enrichment analyses. Additionally, Random Forest machine was applied to identify predictive differentially expressed genes (DEGs) associated with ( 2R,6R )-HNK treatment response. Results: Transcriptomic analysis identified 206 DEGs in morphine-abstinent mice without treatment compared to opioid-naïve controls (MOR-SAL vs. SAL-SAL), implicating altered immune signaling, synaptic function, and structural plasticity. Comparison of opioid-abstinent mice treated with ( 2R,6R )-HNK to opioid-naive controls (MOR-HNK vs. SAL-SAL) revealed 186 residual DEGs, enriched for Th17-mediated immune and fear regulation pathways, suggesting a persistent intermediate molecular phenotype despite normalized behavioural scores. DEGs overlap analysis between MOR-HNK vs . MOR-SAL and MOR-SAL vs . SAL-SAL indicated that ( 2R,6R )-HNK treatment reversed 55 DEGs in opioid-abstinent mice, including Transthyretin ( Ttr ) and T-cell surface glycoprotein ( Cd5 ) expression levels. Machine learning identified interleukin 1 receptor accessory protein-like 1 ( Il1rapl1) and cytotoxic T lymphocyte-associated protein 2 beta ( Ctla2b) as top predictors of ( 2R,6R )-HNK’s treatment response. Notably, while (2R,6R)-HNK induces transcriptional changes in opioid-naive mice (SAL-HNK), it does not affect behavior compared to untreated controls (SAL-SAL). In contrast, its therapeutic effects are evident in morphine-abstinent mice (MOR-HNK), highlighting its context-dependent efficacy. Conclusion: (2R,6R)-HNK promotes both transcriptional and behavioral recovery in opioid-abstinent mice, reversing key gene expression changes. However, persistent dysregulation of neuroimmune and emotion-related pathways suggests an intermediate molecular state, reflecting ongoing recovery.